Bacillus Calmette Guerin (BCG) vaccine-based therapy for pulmonary arterial hypertension: Repurposing tuberculosis vaccine into a pulmonary arterial hypertensive vaccine: BCG, a tuberculosis vaccine, inhibits the development of pulmonary arterial hypertension via down regulation of its target gene Notch3, 1/July/2018, 11.36 pm

Awakening the sleeping/cancer-protecting angels in mutant p53-expressing human tumors: Emodin, isolated from Rhubarb and others,  increases the expression of tumor suppressors genes, such as  TPM1, TA-p73, TAp63, p53, and others, induces regression of p53-mutated human tumors, via down regulation of its target gene, 27/June/2018, 11.08 pm
July 1, 2018
Bacillus Calmette Guerin (BCG) vaccine-based adjunct therapy for cardiac hypertrophy and fibrosis: BCG vaccine decreases MiR-29 expression, activates wnt- signaling and its components GSK3B, ICAT/CTNNBIP1, HBP1 and GLIS2, attenuates pathologic hypertrophy, inhibits fibrosis of the heart tissue, and improves cardiac function, via up regulation of its target gene, 2/July/2018, 11.13 am
July 2, 2018
Show all

What they say: 

A study from the University of California, La Jolla, California, USA shows that Notch3 signaling promotes the development of pulmonary arterial hypertension.” This study was published, in the 15 November  2009 issue of the journal “Nature Medicine”[the number 1 journal in General Medicine with an I.F of 28.054],  by Prof. Thistlethwaite PA, Li X and others.


What we say: 

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that:  Bacillus Calmette Guerin (BCG) vaccine-based therapy for pulmonary arterial hypertension: Repurposing tuberculosis vaccine into a pulmonary arterial hypertensive vaccine: BCG, a tuberculosis vaccine, inhibits the development of pulmonary arterial hypertension via down regulation of its target gene Notch3


Significance of the study:  

This study suggests, first the first time, Bacillus Calmette Guerin (BCG) vaccine-based therapy, with detailed mechanistic insights, for curing pulmonary arterial hypertension. BCG vaccine  has been found to be useful in the treatment of tuberculosis, for more than 100 years, more recently in the treatment of autoimmune diabetes. However, the mechanism of action remains largely unknown

Tuberculosis BCG vaccineby increasing the expression of its target gene, it may decrease the expression of Notch3 and its target gene Hes-5 (Fig.1). Thereby, it may inhibit and promote, respectively, proliferation and differentiation of smooth muscle cells. And, thereby, prevent pulmonary hypertension (Figure 1).  Thus, BCG vaccineeither alone or in combination with other drugs,” may be used to treat/cure pulmonary arterial hypertension (Figure 2). Together, by vaccinating pulmonary hypertensive patients with BCGone may prevent pulmonary arterial hypertension

Figure 1. Mechanistic insights into how  tuberculosis BCG vaccine functions as an anti-pulmonary arterial hypertensive vaccine.  BCG vaccine  may promote insulin sensitivity and protect against myocardial infarction, via up regulation of reprogramming protein Lin-28

Figure 2.   Tuberculosis BCG vaccine may function as an anti-hyperglycemic agent through induction of Lin-28

 


Details of the research findings: 

Idea Proposed/Formulated byDr L Boominathan Ph.D.

Undisclosed mechanistic information: How  BCG vaccine  decreases the expression of Notch3 and its target gene

Amount: $500#

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

For purchase and payment details, you may reach us at info@genomediscovery.org

# Research cooperation


References: 

Web: http://genomediscovery.org or http://newbioideas.com/

CitationBoominathan, L.,  Bacillus Calmette Guerin (BCG) vaccine-based therapy for pulmonary arterial hypertension: Repurposing tuberculosis vaccine into a pulmonary arterial hypertensive vaccine: BCG, a tuberculosis vaccine, inhibits the development of pulmonary arterial hypertension via down regulation of its target gene Notch3, 1/July/2018, 11.36 pm,  Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Courtesy: When you cite us, drop us a line at info@genomediscovery.org

Comments are closed.